Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer

US9095601B2 · kind B2 · utility

Assignee

• Washington University in St. Louis · US

Inventors

• Matthew Becker · Stow, US
• Huafeng Fang · Chesterfield, US
• Xiaoxu Li · New York, US
• Dipanjan Pan · Chesterfield, US
• Raffaella Rossin · Eindhoven, NL
• Xiankai Sun · Coppell, US
• John Taylor · Orange, US
• Jeffrey L. Turner · Chesterfield, US
• Michael J. Welch · Clayton, US
• Karen L. Wooley · College Station, US

Key dates

• Filing date: Dec 5, 2012
• Grant date: Aug 4, 2015
• Expiry date: Dec 5, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2′-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.